The 2025 annual meeting of the American Society of Hematology (ASH) is set for December 6 through December 9 in Orlando, Florida. The 67th ASH Annual Meeting is the world’s most comprehensive hematology event of the year.
Registration is currently open to members, non-members, groups, exhibitors, and media.
With hundreds of sessions to choose from, we took the time to sort through the current schedule and compiled a list of sessions that discuss leukemia and leukemia-related topics. The following schedule rundown is accurate as of November 4, 2025, and includes sessions from the education program and scientific program.
Saturday, December 6
Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges
- 2:00 PM – 3:15 PM
- Description: The introduction of immunotherapies in the last decade has fundamentally changed the treatment of B-cell acute lymphoblastic leukemia (B-ALL), first in the setting of relapse and now in the setting of newly diagnosed disease. In this session, the evidence supporting this change will be reviewed. However, this session will also focus on what comes next. Drs. Kristen O’Dwyer and Sumit Gupta will look at the promise and challenges in de-intensifying treatment by removing elements of traditional therapy in adult and pediatric populations respectively. Dr. Ryan Cassaday will close the session by focusing specifically on the challenge posed by preventing extramedullary relapses in an era of immunotherapy, which may or may not have extramedullary activity.
Cars for Kids: Chimeric Antigen Receptor T-Cell Therapy for Childhood Leukemias
- 2:00 PM – 3:15 PM
- Description: This session will explore the latest translational and clinical advances driving the next generation of CAR-T therapies for childhood leukemias. Together, the talks featured in this session will provide a forward-looking view of how cutting-edge CAR-T innovations are reshaping pediatric leukemia treatment—from B-acute lymphoblastic leukemia (ALL) to acute myeloid leukemia (AML)—and paving the way toward broader, more durable cures.
Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why?
- 4:00 PM – 5:15 PM
- Description: Allogeneic hematopoietic cell transplantation (HCT) is a central component for the curative strategy for many patients with hematologic malignancies. Disease relapse after HCT still occurs, for some diseases with distressing regularity. Therefore, post-HCT maintenance therapies have become increasingly common in both adult and pediatric patients. Knowing which patients might benefit from maintenance therapy, what to use, and when to start such therapy is not well-defined and often controversial. This session will review the data for post-HCT maintenance for acute leukemia, with a particular focus on measurable residual disease (MRD), and offer practical guidance to clinicians on this topic.
Joint Session: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia
- 4:00 PM – 5:35 PM
- Description: The first talk will focus on recent studies using a genome-first approach to define the population prevalence of germline variants in genes causing inherited bone marrow failure syndromes (IBMFS) and leukemia predisposition syndromes and discuss the implications of this expanded recognition of prevalence on our understanding of clinical phenotypes at the population level. The next talk will discuss the mechanisms that underlie somatic clonal progression in IBMFS and how they inform our understanding of disease-specific malignancy risk. The final talk will discuss the expanding understanding of DDX41 in leukemia pathogenesis, highlighting recently described molecular mechanisms.
Sunday, December 7
The Changing Face of Chronic Myelogenous Leukemia
- 4:30 PM – 5:45 PM
- Description: Dr. Jorge Cortes will discuss current recommendations for frontline treatment selection and Dr. Francois-Xavier Mahon will discuss current data around treatment-free remissions and other TKI management strategies, focusing on the management of long-term, TKI-related toxicities (in adult and pediatric patients). Of note, the speakers will ensure that the pediatric perspective is incorporated as well.
Monday, December 8
- 10:30 AM – 11:45 AM
- Description: In less than a decade, immunotherapy has revolutionized the treatment approaches and algorithms for hematologic malignancies. Rapid progress using engineered autologous chimeric antigen receptor T-cells, development of a new generation of antibody-drug conjugates, and the advent of bispecific antibodies with improved delivery features have all had major impact. The first generation of trials with these agents were conducted primarily in the relapsed and refractory setting. However, impressive efficacy and growing experience with managing adverse effects support earlier integration of immunotherapy in treatment paradigms of several blood cancers. There are many remaining challenges and opportunities, and this session features three speakers who will highlight the next chapter for immunotherapies in myeloma, non-Hodgkin lymphoma, and acute leukemias.
Asparaginase in ALL/LBL: Balancing the Risk/Benefit of New Efficacious Preparations
- 10:30 AM – 11:45 AM
- Description: In this session, we will tackle the complexities of balancing the demonstrated benefits of asparaginases with their unique toxicities. Dr. Birgitte Klug Albertsen will focus on hypersensitivity reactions to asparaginase. Dr. Marlise Luskin will review the spectrum of other adverse events that can occur with asparaginase, including pancreatitis, hyperglycemia, hyperlipidemia, and thromboses.
Targeted Therapy for AML (Triplets and More)
- 10:30 AM – 11:45 AM
- Description: This session will focus on three areas with major promise: the addition of approved targeted agents (FLT3 and IDH1 inhibitors) to standard backbones; the emerging data with the newest class of targeted agents (menin inhibitors); and mechanisms to improve outcomes for adults with AML without a targetable mutation.
- 2:45 PM – 4:00 PM
- Description: T-cell engaging immunotherapies have transformed the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). This session will highlight the untapped potential and the emerging questions for these immunotherapies in pediatric hematologic malignancies.
- 2:45 PM – 4:00 PM
- Description: This session will provide a comprehensive overview of both common and rare B-cell malignancies. Experts will present the latest clinical and translational research, offer evidence-based treatment recommendations, and highlight emerging strategies in disease management. Attendees will gain insights into how to apply recent data in clinical practice, tailor therapy to individual patient profiles, and approach rare B-cell disorders where evidence may be limited but is rapidly evolving.
Genomics in Pediatric Acute Leukemia Risk Stratification
- 2:45 PM – 4:00 PM
- Description: Recently, genomic technologies have allowed for the integration of prognostic indels (insertions/deletions), single nucleotide variants (SNVs), transcriptional signatures, and fusion oncoproteins. Improvements in statistical modeling allow for the integration of cooperating genomic lesions in risk algorithms and for age and MRD to be considered as continuous variables instead of dichotomous. This session will discuss recent advances in risk stratification in childhood leukemias.
- 4:30 PM – 5:45 PM
- Description: This session will discuss the phenomenon of ambiguous lineage acute leukemia as a spectrum encompassing multiple leukemia subtypes that are characterized by retained differentiation potential and lineage plasticity.
Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.
Copyright © 2025 Guideline Central, all rights reserved.